Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Cyclophosphamide

Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.

DRUG

Cetuximab

The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT01581970 - Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | Biotech Hunter | Biotech Hunter